Drugs / Nu-3
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07565506 | Aug → Dec 2026 expected | ulcer of lower limbs | Lakewood-Amedex Inc | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06020235 | Dec 2025 → Jun 2026 overdue | — | Lakewood-Amedex Inc | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05276401 | Mar → May 2022 | chronic ulcer of skin | Lakewood-Amedex Inc | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-07-22 | Lakewood-Amedex Inc | Results Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria investorroom.com ↗
Nu-3, a Phase 2-ready candidate targeting the treatment of infected diabetic foot ulcers (iDFU), targets disruption of bacterial membranes through a unique, physical mechanism of action and has demonstrated a high barrier to resistance. |
| 2026-07-15 | Lakewood-Amedex Inc | Results Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel investorroom.com ↗
Nu-3 was well tolerated in the FDA-required safety study after administering dose levels substantially higher than the doses selected for the planned Phase 2a trial. |
| 2026-05-01 | Lakewood-Amedex Inc | Results Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers investorroom.com ↗
In contrast, the MIC for the ciprofloxacin control had increased over 2,000-fold for E. coli and over 600-fold for MRSA. |
| 2025-10-22 | Lakewood-Amedex Inc | Results Lakewood-Amedex Biotherapeutics Announces Peer-Reviewed Publication Demonstrating Potent Antimicrobial Activity of Bisphosphocin® Class Against Resistant Pathogens investorroom.com ↗ |
All press releases naming this drug 12 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nu-3 | “The goal of this clinical trial is to learn if drug Nu-3 works to treat mildly infected diabetic foot ulcers in adults with Type 1 or Type 2 diabetes at 3 different dose levels.” NCT07565506 ↗2“topically administered concentrations of Nu-3 gel in subjects with Type 1 and 2 diabetic non-healing target chronic diabetic foot ulcer (cDFU)” NCT05276401 ↗ |
| Known as | Bisphosphocin | “A prospective, randomized, single-blind Phase 2a multi-center dose comparative study to evaluate the safety, tolerability, and antimicrobial efficacy of topically twice daily...” NCT07565506 ↗2“A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Antimicrobial Efficacy of Topically Once or Twice Daily Applied Bisphosphocin® Nu-3 Gel At...” NCT06020235 ↗ “Topically Applied Bisphosphocin Nu-3 Gel” NCT05276401 ↗ |
| Route | Topical | “topically administered concentrations of Nu-3 gel” NCT05276401 ↗ |